<?xml version='1.0' encoding='utf-8'?>
<document id="21430660"><sentence text="Disease-drug-drug interaction involving tocilizumab and simvastatin in patients with rheumatoid arthritis."><entity charOffset="56-67" id="DDI-PubMed.21430660.s1.e0" text="simvastatin" /></sentence><sentence text="In rheumatoid arthritis (RA), interleukin-6 (IL-6) concentration is elevated, which may cause reduced cytochrome P450 (CYP) activity and increased exposure (peak plasma concentration and area under the plasma concentration-vs" /><sentence text="-time curve (AUC)) to certain drugs" /><sentence text=" Tocilizumab may reverse IL-6-induced suppression of CYP3A4 activity" /><sentence text=" In this study, exposure to simvastatin was significantly reduced at 1 and 5 weeks after tocilizumab infusion in 12 patients with RA"><entity charOffset="28-39" id="DDI-PubMed.21430660.s5.e0" text="simvastatin" /></sentence><sentence text=" The mean effect ratio for simvastatin AUC(last) was 43% (90% confidence interval (CI), 34-55%) at 1 week after tocilizumab infusion (day 15) and 61% (90% CI, 47-78%) at 5 weeks after tocilizumab infusion, as compared with baseline (day 1); both ratios were significantly lower than the bioequivalence boundary (80-125%)"><entity charOffset="27-38" id="DDI-PubMed.21430660.s6.e0" text="simvastatin" /></sentence><sentence text=" Mean plasma C-reactive protein (CRP) levels normalized within 1 week after tocilizumab was initiated; the time course of tocilizumab's CRP-reducing effect paralleled that of simvastatin pharmacokinetics"><entity charOffset="175-186" id="DDI-PubMed.21430660.s7.e0" text="simvastatin" /></sentence><sentence text=" The study findings suggest that caution should be exercised when starting tocilizumab in RA patients who are taking simvastatin"><entity charOffset="117-128" id="DDI-PubMed.21430660.s8.e0" text="simvastatin" /></sentence><sentence text="" /></document>